Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives

Hernández-Alcoceba, Rubén; Sangro, Bruno; Berraondo, Pedro; González‐Aseguinolaza, Gloria; Prieto, Jesús

doi:10.1517/13543784.2013.793307

Cited by 6 publications

(2 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therapeutic approaches employing cytokines, immune checkpoint inhibitors, and chimeric antigen receptor T cells (CAR-T) are commonly employed. Cytokines, such as IFNα, IFNγ, IL-2, and GM-CSF, which induce B cells, T cells, NK cells, and macrophages for tumor cell killing, have been successfully used for gastrointestinal cancer treatment [153]. The two immune checkpoint inhibitors target PD-1/PD-L1 and CTLA4.…”

Section: Immunotherapymentioning

confidence: 99%

Association between Inflammation and Function of Cell Adhesion Molecules Influence on Gastrointestinal Cancer Development

Huang

Chang

Wang

et al. 2021

Cells

View full text Add to dashboard Cite

Gastrointestinal cancer is highly associated with inflammatory processes inducing the release of cytokines from cancer or immune cells, including interferons, interleukins, chemokines, colony-stimulating factors, and growth factors, which promote or suppress tumor progression. Inflammatory cytokines within the tumor microenvironment promote immune cell infiltration. Infiltrating immune, and tumor-surrounding stromal cells support tumor growth, angiogenesis, metastasis, and immunosuppression through communication with inflammatory cytokines and cell adhesion molecules. Notably, infiltrating immune and tumor cells present immunosuppressive molecules, such as programmed death-ligand 1 (PD-L1) and CD80/CD86. Suppression of cytotoxic T cells promotes tumor avoidance of immune surveillance and greater malignancy. Moreover, glycosylation and sialylation of proteins hyperexpressed on the cancer cell surface have been shown to enhance immune escape and metastasis. Cytokine treatments and immune checkpoint inhibitors are widely used in clinical practice. However, the tumor microenvironment is a rapidly changing milieu involving several factors. In this review, we have provided a summary of the interactions of inflammation and cell adhesion molecules between cancer and other cell types, to improve understanding of the tumor microenvironment.

show abstract

Section: Immunotherapymentioning

confidence: 99%

Association between Inflammation and Function of Cell Adhesion Molecules Influence on Gastrointestinal Cancer Development

Huang

Chang

Wang

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…Cytokines are secreted proteins used by immune system cells for intercellular communication. A number of them have potent immunostimulatory and antineoplastic activities in animal models and the results of several Phase I and II clinical trials in patients with gastrointestinal cancer have been reported and recently reviewed [47]. IFN-α was initially considered a promising treatment for cancer -and specifically for HCC -due to its antiproliferative, proapoptotic and immunomodulatory activities.…”

Section: • • Cytokinesmentioning

confidence: 99%

Immunotherapy of Hepatocellular Carcinoma

2014

Self Cite

View full text Add to dashboard Cite

Newer immunotherapy agents may break the barrier that tumors create to evade the attack from the immune system. Dendritic cell vaccination has shown encouraging clinical activity and a favorable safety profile in advanced tumor stages. However, optimal cell maturation status, choice of tumor antigens and route of administration have not been established. Single or multiple peptides derived from tumor-associated antigens may also be used for cancer vaccination. Intratumoral delivery of oncolytic viruses expressing immunostimulating cytokines like GM-CSF have produced stimulating clinical results that need further verification. But it is probably T-cell checkpoint modulation with monoclonal antibodies that has attracted the highest expectations. Promising activity has been reported for tremelimumab, a CTLA-4 inhibitor, and a clinical trial testing the PD-1 antibody nivolumab is underway. Future progress will probably come from a better understanding of the mechanisms of cancer-related immunosuppression, improvement in agents and strategies and combination of the available therapeutic tools.

show abstract

The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116

et al. 2015

View full text Add to dashboard Cite

Colorectal cancer is one of the most common malignant diseases and is a leading cause of cancer mortality in the Western world. Primary or acquired resistance to chemotherapeutic drugs is a common phenomenon which causes a failure in cancer treatment. A diverse range of molecular mechanisms has been implicated in drug resistance: DNA damage repair, alterations in drug metabolism, mutation of drug targets, increased rates of drug efflux, and activation of survival signaling pathways. The aim of this study was to investigate the expression of CXCL8-CXCR1/2 pathway, its impact on cell proliferation and cytokine expression in human colorectal carcinoma HCT116 cells, and their chemotherapy-resistant subline. We found that IL-1 alpha stimulates the production of CXCL8 through IL-1 receptor signaling. Our data indicate that CXCL8 is upregulated in chemoresistant subline of colorectal cancer cells HCT116, and modulation of CXCR2 pathway can be a target for proliferation inhibition of chemoresistant colorectal cancer cells.

show abstract

Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives

Cited by 6 publications

References 92 publications

Association between Inflammation and Function of Cell Adhesion Molecules Influence on Gastrointestinal Cancer Development

Association between Inflammation and Function of Cell Adhesion Molecules Influence on Gastrointestinal Cancer Development

Immunotherapy of Hepatocellular Carcinoma

The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116

Contact Info

Product

Resources

About